Influenza Virus Nucleoprotein Antikörper (Influenza A Virus)

Produktnummer ABIN7794943

Der Maus Monoklonal anti-Influenza Virus Nucleoprotein Antikörper (Klon 1114) (ABIN7794943) detektiert spezifisch Influenza Virus Nucleoprotein. Dieser Antikörper reagiert spezifisch mit Proben aus Influenza A Virus.

Kurzübersicht für Influenza Virus Nucleoprotein Antikörper (Influenza A Virus) (ABIN7794943)

Target: Influenza Virus Nucleoprotein (IV NP)

Reaktivität: Influenza A Virus

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: Bitte anfragen

Klon: 1114

Produktdetails

Verwendungszweck: Anti-Influenza A, Nucleocapsid (Clone 1114) Purified No Carrier Protein

Spezifität: Anti-Influenza A, Nucleocapsid (Clone 1114) specifically targets an epitope on the Influenza A Nucleocapsid Protein Antigen Distribution The nucleocapsid protein is expressed in the internal nucleocapsid of Influenza A Background There are four types of Influenza (flu) viruses type A, B, C, and D. Influenza A and B viruses are routinely spread in people and other mammals, while also known for seasonal flu epidemics each year. Influenza A is the genus Alphainfluenzavirus of the virus family Orthomyxoviridae. Influenza A is classified into two main protein subtypes, hemagglutinin (HA) and neuraminidase (NA), located on the surface of the virus. Breaking down the proteins further, there are 18 hemagglutinin subtypes and 11 different neuraminidase subtypes1. Influenza A can be even further classified into specific clades (also known as groups) and sub-clades (also known as sub-groups) based on similarity of their HA/NA gene sequences1. The Nucleocapsid protein or nucleoprotein (NP) of the influenza virus A negative-strand RNA?s primary function is to encapsulate the virus genome for the purpose of RNA transcription, replication and packaging2. Specifically, NP is the most abundant viral protein in infected cells2, therefore the NP can be and has been used for anti-influenza drug development3 The NP of influenza A and B viruses share up to 38 % of their amino acid sequence, indicating region functionality differences at the amino acid level4

Aufreinigung: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Reinheit: >=90 % monomer by analytical SEC and SDS-Page

Isotyp: IgG1

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 μg/mL

Buffer: This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Konservierungsmittel: Without preservative

Lagerung: 4 °C,-80 °C

Informationen zur Lagerung: This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at <= -70°C.Avoid Repeated Freeze Thaw Cycles.

Antigendetails

Target: Influenza Virus Nucleoprotein (IV NP)

Andere Bezeichnung: Influenza A Virus Nucleocapsid

Substanzklasse: Influenza Protein

Hintergrund: Common flu NP, Influenza A virus NP, NP, Nucleocapsid protein, Nucleoprotein, Protein N, Seasonal Influenza A (H1N1) Nucleocapsid Protein,